Bli medlem
Bli medlem

Du är här

2015-03-30

MorphoSys AG: MorphoSys Nominates Three New Candidates for Supervisory Board

MorphoSys AG / MorphoSys Nominates Three New Candidates for Supervisory Board.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) published today its
agenda for the Company's ordinary Annual General Meeting, which will take
place on Friday, May 8, 2015. MorphoSys's Supervisory Board nominated Ms.
Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich as candidates to be
elected as new members at the Company's AGM 2015. Ms. Johnson, Mr. Kühn and
Dr. Morich will replace Dr. Walter Blättler, Dr. Daniel Camus and Dr.
Geoffrey Vernon. Dr. Vernon has been a member of MorphoSys AG's Supervisory
Board since 1999, while Dr. Camus and Dr. Blättler joined in 2002 and 2007,
respectively.

"We are delighted to be able to present three highly qualified candidates,
each with extensive industry expertise, for MorphoSys's Supervisory Board.
The three new candidates bring to our Board significant experience in
pharmaceutical drug development and commercialization, finance and accounting
as well as business development," commented Dr. Gerald Möller, Chairman of
the Supervisory Board of MorphoSys AG. "On behalf of the Company, I would
like to thank Dr. Walter Blättler, Dr. Daniel Camus and Dr. Geoffrey Vernon
for their invaluable support over many years in establishing MorphoSys as one
of the world's leading therapeutic antibody companies."

Ms. Wendy Johnson currently serves as Managing Director of Gemini Advisors and
Interim Chief Operating Officer and Member of the Board of Directors of
AmpliPhi BioSciences. Previously, she was a venture partner at ProQuest
Investments, a healthcare-focused venture capital firm. She also founded and
served as the President and Chief Executive Officer of Aires Pharmaceuticals.
Prior to joining ProQuest, she served as Senior Vice President, Corporate
Development, at Salmedix Inc., where she was involved in the clinical
development of the company's oncology portfolio including the cancer drug
bendamustine. Before her time at Salmedix she held various senior business
and corporate development positions and served as Assistant Director with the
Center for Devices and Radiological Health at the U.S. Food and Drug
Administration. Ms. Johnson holds an M.B.A. from Loyola University, an M.S.
in clinical microbiology from the Hahnemann Medical School and a B.S. in
microbiology from the University of Maryland.

Mr. Klaus Kühn, former Chief Financial Officer of Bayer AG, has more than 30
years of experience in executive positions, primarily in the chemical and
pharmaceutical industry with a focus on finance and accounting. Before his
appointment as CFO, he served as Head of Finance at Bayer AG and oversaw the
spin-off and subsequent IPO of the group's former Agfa division. Prior to his
time with Bayer, he was Head of Corporate Staff and Head of Finance at
Schering AG. In the biotechnology industry he previously held positions on
the Supervisory Boards of 4SC AG and MediGene AG. He currently holds
positions on the Supervisory Boards of Flossbach von Storch AG and Hella KGaA
Hueck&Co. Mr. Kühn studied Mathematics and Physics at Technical University of
Berlin and holds an M.B.A. in International Business Studies from the
University of South Carolina, Columbia, U.S.A.

Dr. Frank Morich, M.D., Ph.D. was most recently Chief Commercial Officer and
Member of the Board of Directors of Takeda Pharmaceutical Company Ltd.,
Tokyo, Japan, as well as Chief Executive Officer of Takeda Pharmaceutical
International GmbH. Previously, he served as Executive Vice President of
International Operations for Americas/Europe at Takeda Pharmaceuticals
International, Inc. Before his time at Takeda, Dr. Morich served as Chief
Executive Officer of NOXXON Pharma AG from and as Chief Executive Officer and
member of the Board of Directors of Innogenetics NV. Between 1982 and 2002 he
held various R&D and senior management positions in the Bayer Group. In 2000,
he was appointed member of the Management Board of Bayer AG and member of the
Board of Directors of Bayer Corp., USA. In 2002, Dr. Morich was elected
Chairman of the Board of Management and Executive Committee for Bayer
Healthcare AG. Dr. Morich studied medicine at the University of Marburg in
Germany, specializing in immunology and oncology.

The full agenda for the Annual General Meeting is available on the Company's
website underwww.morphosys.com/agm.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 90 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla
®, Ylanthia®and 100 billion high potentials®are registered trademarks of
MorphoSys AG.

Slonomics®is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications&IR

Mario Brkulj

Associate Director Corporate Communications&IR

Alexandra Goller

Manager Corporate Communications&IR

Jessica Rush

Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com

Media Release (PDF)
http://hugin.info/130295/R/1907403/679395.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1907403

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.